Extended Data Table 1 Deep-sequence analysis of NA protein amino acid substitutions in virus-positive brain or lung tissue

From: Baloxavir improves disease outcomes in mice after intranasal or ocular infection with Influenza A virus H5N1-contaminated cow’s milk

Mouse ID

Tissue

Inoculation route

Treatment regimen

PA a.a changea, b (% Frequency, read count/coverage)

76

Brain

Ocular

OSE 200 mg/kg

No Changes

99

Brain

Oral

OSE 200 mg/kg

No Changes

100

Brain

Oral

OSE 200 mg/kg

No Changes

109

Brain

Oral

OSE 20 mg/kg

No Changes

110

Brain

Oral

OSE 20 mg/kg

No Changes

111

Brain

Oral

OSE 20 mg/kg

No Changes

120

Brain

Intranasal

OSE 200 mg/kg

No Changes

121

Brain

Intranasal

OSE 200 mg/kg

No Changesc

122

Brain

Intranasal

OSE 200 mg/kg

No Changes

134

Brain

Intranasal

OSE 20 mg/kg

No Changesc

135

Brain

Intranasal

OSE 20 mg/kg

No Changes

136

Brain

Intranasal

OSE 20 mg/kg

No Changes

145

Brain

Ocular

Non-treated

K257T (6.6%, 307/4624)

146

Brain

Ocular

Non-treated

No Changes

147

Brain

Ocular

Non-treated

No Changes

156

Brain

Oral

Non-treated

No Changes

157

Brain

Oral

Non-treated

No Changes

158

Brain

Oral

Non-treated

No Changes

167

Brain

Intranasal

Non-treated

No Changesc

168

Brain

Intranasal

Non-treated

No Changes

60

Brain

Intranasal

Non-treated

No Changes

76

Lung

Ocular

OSE 200 mg/kg

No Changes

89

Lung

Ocular

OSE 20 mg/kg

No Changes

99

Lung

Oral

OSE 200 mg/kg

No Changes

100

Lung

Oral

OSE 200 mg/kg

No Changes

109

Lung

Oral

OSE 20 mg/kg

No Changes

110

Lung

Oral

OSE 20 mg/kg

No Changes

111

Lung

Oral

OSE 20 mg/kg

No Changes

120

Lung

Intranasal

OSE 200 mg/kg

No Changes

121

Lung

Intranasal

OSE 200 mg/kg

No Changesc

122

Lung

Intranasal

OSE 200 mg/kg

No Changes

134

Lung

Intranasal

OSE 20 mg/kg

No Changes

135

Lung

Intranasal

OSE 20 mg/kg

No Changes

136

Lung

Intranasal

OSE 20 mg/kg

No Changes

145

Lung

Ocular

Non-treated

K257T (6.5%, 277/4246)

146

Lung

Ocular

Non-treated

D284N (12.6%, 487/3861)

147

Lung

Ocular

Non-treated

No Changes

156

Lung

Oral

Non-treated

No Changes

157

Lung

Oral

Non-treated

No Changes

158

Lung

Oral

Non-treated

No Changes

167

Lung

Intranasal

Non-treated

No Changesc

168

Lung

Intranasal

Non-treated

No Changes

60

Lung

Intranasal

Non-treated

No Changes

  1. aIdentified from Illumina sequencing of NA fragments comprising nucleotides 1-1413
  2. bAmino acid variant calling in CLC Genomics was performed with a variant frequency cutoff of 5% for ≥1000 reads at the target region
  3. cSample contained 1 synonymous change in the coding region
  4. a.a. = amino acid.